Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O95848

UPID:
NUD14_HUMAN

ALTERNATIVE NAMES:
Nucleoside diphosphate-linked moiety X motif 14

ALTERNATIVE UPACC:
O95848; Q86SJ8

BACKGROUND:
The enzyme Uridine diphosphate glucose pyrophosphatase NUDT14, alternatively named Nucleoside diphosphate-linked moiety X motif 14, is integral to the hydrolysis of UDP-glucose and ADP-ribose, crucial for maintaining cellular energy balance and metabolic functions. It exhibits specificity towards UDP-glucose, with poor activity on substrates such as CDP-glucose and GDP-mannose.

THERAPEUTIC SIGNIFICANCE:
Exploring the enzymatic activity of Uridine diphosphate glucose pyrophosphatase NUDT14 unveils potential avenues for therapeutic intervention. By elucidating its role in metabolic pathways, researchers can identify novel drug targets, contributing to the development of treatments for metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.